Nigrostriatal dopamine terminal imaging with dopamine transporter SPECT: An update

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1331-1338

  Tatsch, Klaus ^a   Poepperl, Gabriele ^b  

^a Municipal Hospital Karlsruhe   (Germany)

^b KATHARINENHOSPITAL   (Germany)

Author keywords

Dopamine transporter; Lewy body dementia; Parkinsonian syndromes; Primary and secondary parkinsonism; Single photon emission computed tomography; Tremor syndromes

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; HALOPERIDOL; NEUROLEPTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ALZHEIMER DISEASE; ARTICLE; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; EARLY DIAGNOSIS; ECONOMIC ASPECT; EXTRAPYRAMIDAL SYMPTOM; HISTOPATHOLOGY; HUMAN; NIGRONEOSTRIATAL SYSTEM; PARKINSONISM; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA PARS COMPACTA; SYNAPTOSOME;

DOPAMINE TRANSPORTER; LEWY BODY DEMENTIA; PARKINSONIAN SYNDROMES; PRIMARY AND SECONDARY PARKINSONISM; SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY; TREMOR SYNDROMES;

ANIMALS; BRAIN; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; NEURODEGENERATIVE DISEASES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84881394948     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.105379     Document Type: Article

References (82)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
2. 123Iioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord. 2004;19:1175-1182.
3. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861-870.
4. 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305-313.
5. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing. 1999;28:99-102.
6. Au WL, Adams JR, Troiano A, Stoessl AJ. Neuroimaging in Parkinson's disease. J Neural Transm Suppl. 2006;70:241-248.
7. Hotter A, Esterhammer R, Schocke MF, Seppi K. Potential of advanced MR imaging techniques in the differential diagnosis of parkinsonism. Mov Disord. 2009;24(suppl 2):S711-S720.
8. Seppi K, Poewe W. Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin N Am. 2010;20:29-55.
9. Lehéricy S, Sharman MA, Dos Santos CL, Paquin R, Gallea C. Magnetic resonance imaging of the substantia nigra in Parkinson's disease. Mov Disord. 2012;27:822-830.
10. Cochrane CJ, Ebmeier KP. Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology. 2013;80:857-864.
11. Varrone A, Halldin C. New developments of dopaminergic imaging in Parkinson's disease. Q J Nucl Med Mol Imaging. 2012;56:68-82.
12. Seibyl J, Russell D, Jennings D, Marek K. The molecular basis of dopaminergic brain imaging in Parkinson's disease. Q J Nucl Med Mol Imaging. 2012;56:4-16.
13. Brooks DJ. Neuroimaging in Parkinson's disease. NeuroRx. 2004;1:243-254.
14. Frey KA, Koeppe RA, Kilbourn MR. Imaging the vesicular monoamine transporter. Adv Neurol. 2001;86:237-247.
15. Okamura N, Villemagne VL, Drago J, et al. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with 18F-AV-133. J Nucl Med. 2010;51:223-228.
16. 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443-450.
17. 123I-ioflupane SPECT 1.0. J Nucl Med. 2012;53: 154-163.
18. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med. 1999;26:171-182.
19. Pavese N, Khan NL, Scherfler C, et al. Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study. Mov Disord. 2009;24:2260-2266.
20. Ribeiro MJ, Thobois S, Lohmann E, et al. A multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations. J Nucl Med. 2009;50:1244-1250.
21. 123I]FP-CIT SPECT in early-onset parkin disease. Neurology. 2004; 63:2097-2103.
22. 123I]-FP-CIT study group. Mov Disord. 2000;15:503-510.
23. 123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996;46:231-237.
24. 123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease. Eur J Nucl Med Mol Imaging. 2005;32:689-695.
25. 123I] IPT and single-photon emission tomography. Eur J Nucl Med. 1997;24:415-421.
26. Stoessl AJ. Positron emission tomography in premotor Parkinson's disease. Parkinsonism Relat Disord. 2007;13(suppl 3):S421-S424.
27. Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain. 2005;128:2777-2785.
28. 18F]dopa PETand clinical study. Brain. 2002;125:2248-2256.
29. 18F]6-fluorodopa PET. J Neurol. 2000;247(suppl 2):II110-II113.
30. Piccini P, Morrish PK, Turjanski N, et al. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol. 1997;41:222-229.
31. Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord. 2007;22:2210-2215.
32. Bajaj NP, Gontu V, Birchall J, Patterson J, Grosset DG, Lees AJ. Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study. J Neurol Neurosurg Psychiatry. 2010;81:1223-1228.
33. Mian OS, Schneider SA, Schwingenschuh P, Bhatia KP, Day BL. Gait in SWEDDs patients: comparison with Parkinson's disease patients and healthy controls. Mov Disord. 2011;26:1266-1273.
34. Schwingenschuh P, Ruge D, Edwards MJ, et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord. 2010;25:560-569.
35. 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases. J Neurol. 2011;258:2147-2154.
36. Eckert T, Feigin A, Lewis DE, Dhawan V, Frucht S, Eidelberg D. Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging. Mov Disord. 2007;22:167-173.
37. Tatsch K. Extrapyramidal syndromes: PET and SPECT. Neuroimaging Clin N Am. 2010;20:57-68.
38. Pirker W, Djamshidian S, Asenbaum S, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord. 2002;17:45-53.
39. Booij J, Teune LK, Verberne HJ. The role of molecular imaging in the differential diagnosis of parkinsonism. Q J Nucl Med Mol Imaging. 2012;56:17-26.
40. Brooks DJ. Imaging dopamine transporters in Parkinson's disease. Biomark Med. 2010;4:651-660.
41. Koch W, Hamann C, Radau PE, Tatsch K. Does combined imaging of the preand postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism? Eur J Nucl Med Mol Imaging. 2007; 34:1265-1273.
42. la Fougère C, Popperl G, Levin J, et al. The value of the dopamine D2/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes. J Nucl Med. 2010;51:581-587.
43. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005;26:912-921.
44. 123I]IBZMSPECT for the differential diagnosis of parkinsonism. Neurology. 2012;79: 1314-1322.
45. 123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266-272.
46. 123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry. March 13, 2013 [Epub ahead of print].
47. 123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes. J Neuroimaging. 2012;22: 225-230.
48. Gerasimou G, Costa DC, Papanastasiou E, et al. SPECT study with I-123-ioflupane (DaTSCAN) in patients with essential tremor: is there any correlation with Parkinson's disease? Ann Nucl Med. 2012;26:337-344.
49. Trocello JM, Zanotti-Fregonara P, Roze E, et al. Dopaminergic deficit is not the rule in orthostatic tremor. Mov Disord. 2008;23:1733-1738.
50. Vaamonde J, Garcia A, Flores JM, Ibanez R, Gargallo L. Study via presynaptic nigrostriatal using 123-I-FP-CIT-SPECT (DaTSCAN SPECT) in primary orthostatic tremor. Neurologia. 2006;21:37-39.
51. 123I]-FP- CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor. Ann Neurol. 2003;53:489-496.
52. Coria F, Gimenez-Garcia M, Samaranch L, Mora FJ, Sampol-Bas C, Pastor P. Nigrostriatal dopaminergic function in subjects with isolated action tremor. Parkinsonism Relat Disord. 2012;18:49-53.
53. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord. 2003;18:1415-1423.
54. 123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord. 2002;17:518-523.
55. Marshall V, Grosset DG. Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. Mov Disord. 2003;18(suppl 7):S22-S27.
56. 123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease. Mov Disord. 2007;22:1278-1285.
57. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med. 2004;45:1688-1693.
58. 123I]FP-CIT- SPECT asymmetry index to differentiate Parkinson's disease from vascular parkinsonism. Acta Neurol Scand. 2012;126:12-16.
59. 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. Eur J Nucl Med Mol Imaging. 2010;37:556-564.
60. 123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord. 2006;21:510-514.
61. 123I]FP-CIT SPET imaging in druginduced Parkinsonism. Mov Disord. 2008;23:1825-1829.
62. 123I-ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism. Mov Disord. 2006;21:1994-1998.
63. Ouchi Y, Nakayama T, Kanno T, Yoshikawa E, Shinke T, Torizuka T. In vivo presynaptic and postsynaptic striatal dopamine functions in idiopathic normal pressure hydrocephalus. J Cereb Blood Flow Metab. 2007;27:803-810.
64. 123I]beta-CIT single-photon emission computed tomography is normal in doparesponsive dystonia. Ann Neurol. 1998;43:792-800.
65. 123I]beta-CIT single-photon emission tomography in DOPA-responsive dystonia. Mov Disord. 1997;12:448-451.
66. Tatsch K. Imaging of the dopaminergic system in differential diagnosis of dementia. Eur J Nucl Med Mol Imaging. 2008;35(suppl 1):S51-S57.
67. Suzuki M, Desmond TJ, Albin RL, Frey KA. Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias. Ann Neurol. 2002;51:767-771.
68. O'Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol. 2004;61:919-925.
69. Walker Z, Costa DC, Walker RW, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry. 2002;73:134-140.
70. 123I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord. 2012;18:225-229.
71. 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry. 2009;194: 34-39.
72. Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78:1176-1181.
73. Warr L,Walker Z. Identification of biomarkers in Lewy-body disorders. Q J Nucl Med Mol Imaging. 2012;56:39-54.
74. Morgan S, Kemp P, Booij J, et al. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry. 2012;83:1063-1070.
75. 123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013;40:213-227.
76. 123I]FP- CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2008;35:424-438.
77. Hesse S, Oehlwein C, Barthel H, et al. Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. J Neural Transm. 2006;113:1177-1190.
78. Newman EJ, Breen K, Patterson J, Hadley DM, Grosset KA, Grosset DG. Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. Mov Disord. 2009;24:2379-2385.
79. Dodel RC, Hoffken H, Moller JC, et al. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. Mov Disord. 2003;18(suppl 7):S52-S62.
80. 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging. 2008;35:1367-1376.
81. 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. Mov Disord. 2008;23: 2202-2209.
82. Kupsch AR, Bajaj N, Weiland F, et al. Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. J Neurol Neurosurg Psychiatry. 2012;83:620-628.